论文部分内容阅读
日本三菱-东京(Mitsubishi-Tokyo)制药公司新颖的神经保护药Radicut(依达拉奉,edaravone)已经获准在日本首次上市,并因一举赢得了创新药溢价上市的特权而广受市场注目。这是日本自现行补贴计算系统在1995年引进以来第一个获得此殊荣的产品。该公司预测,Radicut在日本的销售额峰
Japan’s Mitsubishi-Tokyo Pharmaceutical Company’s novel neuroprotective drug Radicut (edaravone) has been approved to be listed in Japan for the first time, and has received wide market attention because it has won the privilege of listing innovative drugs at a premium price. This is the first product in Japan since the introduction of the current subsidy calculation system in 1995. The company predicts that Radicut’s sales peak in Japan